{"DataElement":{"publicId":"6344592","version":"1","preferredName":"Disease Response LYRIC Criteria Outcome","preferredDefinition":"The result of the patient's disease to treatment using a tumor response criteria for immunomodulatory therapies designed to account for tumor flares.","longName":"LYRIC_OUTCM","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2014027","version":"1","preferredName":"Disease Response","preferredDefinition":"The response of the patient's disease to treatment.","longName":"DZ_RESP","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2177151","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A disease is any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function. (from Wikipedia)","longName":"Disease","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A50-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Updated to add EVS concept preferred name. dw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177336","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-528C-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Denise Warzel updated Definition by seraching NCI Thesaurus in Admin tool.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"B30B3290-652F-11A0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"HARTLEYG","dateModified":"2018-06-06","changeDescription":"8/30/17 jk transferred context, updated case in defintion first word, and added registration status, CSI per Round 5 finalization task.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6344580","version":"1","preferredName":"Lymphoma Response to Immunomodulatory Therapy Criteria Outcome","preferredDefinition":"A tumor response criteria for immunomodulatory therapies designed to account for tumor flares._The result of an action.","longName":"6344580v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"3","maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IR1","valueDescription":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 1","ValueMeaning":{"publicId":"6344583","version":"1","preferredName":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 1","longName":"6344583","preferredDefinition":"An increase in overall tumor burden of greater than or equal to 50 percent of up to six measurable lesions in the first 12 weeks of therapy, without clinical deterioration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 1","conceptCode":"C153153","definition":"An increase in overall tumor burden of greater than or equal to 50 percent of up to six measurable lesions in the first 12 weeks of therapy, without clinical deterioration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCE73B8-69B9-7DC7-E053-F662850AFC11","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"TAYLORT","dateModified":"2018-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FCED95F-AA72-2090-E053-F662850A6DCC","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","deletedIndicator":"No"},{"value":"PD","valueDescription":"Progressive Disease","ValueMeaning":{"publicId":"3284666","version":"1","preferredName":"Progressive Disease","longName":"3284666v1.00","preferredDefinition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AD9FC7D6-531D-BE97-E040-BB89AD437875","latestVersionIndicator":"Yes","beginDate":"2011-09-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-09-23","modifiedBy":"MMADDINENI","dateModified":"2024-02-22","changeDescription":null,"administrativeNotes":"2023.5.17 Alt VM added per ticket request CADSR0002435. ak \r\n2023.3.15 Per LS at COG Protocol defined progressive disease (should have been added as a VM Alt Name for PV 3284666). ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FCED95F-AA87-2090-E053-F662850A6DCC","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","deletedIndicator":"No"},{"value":"IR3","valueDescription":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 3","ValueMeaning":{"publicId":"6344590","version":"1","preferredName":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 3","longName":"6344590","preferredDefinition":"An increase in F-fluorodeoxyglucose (FDG) uptake of one or more lesions without a concomitant increase in lesion size or number.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 3","conceptCode":"C153155","definition":"An increase in F-fluorodeoxyglucose (FDG) uptake of one or more lesions without a concomitant increase in lesion size or number.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCED95F-AA93-2090-E053-F662850A6DCC","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FCED95F-AAAB-2090-E053-F662850A6DCC","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","deletedIndicator":"No"},{"value":"IR2","valueDescription":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 2","ValueMeaning":{"publicId":"6344591","version":"1","preferredName":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 2","longName":"6344591","preferredDefinition":"The appearance of new lesions or growth of one or more existing lesions greater than or equal to 50 percent at any time during treatment occurring in the context of lack of overall progression of overall tumor burden.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma Response to Immunomodulatory Therapy Criteria Indeterminate Response 2","conceptCode":"C153154","definition":"The appearance of new lesions or growth of one or more existing lesions greater than or equal to 50 percent at any time during treatment occurring in the context of lack of overall progression of overall tumor burden.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCED95F-AAB8-2090-E053-F662850A6DCC","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FCED95F-AAD0-2090-E053-F662850A6DCC","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2233241","version":"1","preferredName":"Medical Imaging","preferredDefinition":"Events, people, materials and activities uniquely defined by medical imaging.  ","longName":"MEDICAL IMAGING","context":"CIP","contextVersion":"2.31","origin":"DICOM:Digital Imaging and Communications in Medicine","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96173D7-A9B4-3CBB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-12","modifiedBy":"SBREXT","dateModified":"2006-09-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6344589","version":"1","preferredName":"Lymphoma Response to Immunomodulatory Therapy Criteria Outcome","preferredDefinition":"A tumor response criteria for immunomodulatory therapies designed to account for tumor flares.:The result of an action.","longName":"C153152:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma Response to Immunomodulatory Therapy Criteria","conceptCode":"C153152","definition":"A tumor response criteria for immunomodulatory therapies designed to account for tumor flares.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCED95F-AA06-2090-E053-F662850A6DCC","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"ONEDATA","dateModified":"2018-06-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCE73B8-6950-7DC7-E053-F662850AFC11","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.; 6/29/18 tt / 10106 & 10126,","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If Response is Progressive Di","type":"Preferred Question Text","description":"If Response is Progressive Disease (per Lugano Criteria), what is the disease response for this evaluation period per LYRIC Criteria?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FCF1AB1-4D38-6D28-E053-F662850A2629","latestVersionIndicator":"Yes","beginDate":"2018-06-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-06-29","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.; 6/29/18 tt/ 10106 & 10126.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}